Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).

Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and older. Budesonide capsules will be produced at is Zydus Pharmaceuticals Ltd, SEZ-II.

The group now has 425 approvals and has so far filed 487* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 972.85 as compared to the previous close of Rs. 980.75. The total number of shares traded during the day was 19334 in over 1311 trades.

The stock hit an intraday high of Rs. 987.35 and intraday low of 968.80. The net turnover during the day was Rs. 18910696.00.

(*As on 30-Sept-25)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals TentativeApproval USFDA Budesonide DelayedRelease Capsules